Gilead Sciences, Inc. (NASDAQ:GILD) CFO Sells $260,225.00 in Stock

Gilead Sciences, Inc. (NASDAQ:GILD) CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction on Tuesday, February 18th. The stock was sold at an average price of $104.09, for a total transaction of $260,225.00. Following the completion of the sale, the chief financial officer now owns 169,061 shares of the company’s stock, valued at approximately $17,597,559.49. This trade represents a 1.46 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Gilead Sciences Price Performance

Shares of Gilead Sciences stock traded up $2.40 on Wednesday, hitting $107.65. The company had a trading volume of 6,298,340 shares, compared to its average volume of 7,370,583. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $107.81. The company has a market cap of $134.16 billion, a PE ratio of 290.95, a PEG ratio of 0.87 and a beta of 0.18. The business has a 50-day simple moving average of $94.39 and a 200-day simple moving average of $88.09. The company has a debt-to-equity ratio of 1.24, a current ratio of 1.50 and a quick ratio of 1.20.

Gilead Sciences (NASDAQ:GILD) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.90 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.67 by $0.23. Gilead Sciences had a return on equity of 31.63% and a net margin of 1.67%. Research analysts expect that Gilead Sciences, Inc. will post 7.94 EPS for the current fiscal year.

Gilead Sciences Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, March 28th. Investors of record on Friday, March 14th will be issued a dividend of $0.79 per share. This is a positive change from Gilead Sciences’s previous quarterly dividend of $0.77. This represents a $3.16 dividend on an annualized basis and a yield of 2.94%. The ex-dividend date is Friday, March 14th. Gilead Sciences’s payout ratio is presently 832.43%.

Institutional Investors Weigh In On Gilead Sciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Toronto Dominion Bank boosted its position in shares of Gilead Sciences by 11.0% during the 4th quarter. Toronto Dominion Bank now owns 710,523 shares of the biopharmaceutical company’s stock valued at $65,631,000 after purchasing an additional 70,551 shares in the last quarter. Formidable Asset Management LLC bought a new stake in shares of Gilead Sciences during the 4th quarter worth $212,000. North Star Asset Management Inc. acquired a new position in shares of Gilead Sciences in the 4th quarter worth $201,000. Cache Advisors LLC acquired a new stake in shares of Gilead Sciences during the fourth quarter worth $1,008,000. Finally, GF Fund Management CO. LTD. purchased a new stake in shares of Gilead Sciences during the fourth quarter valued at $26,266,000. 83.67% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. BMO Capital Markets lifted their target price on Gilead Sciences from $110.00 to $115.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Bank of America reiterated a “buy” rating and set a $109.00 target price on shares of Gilead Sciences in a research note on Tuesday, December 10th. Citigroup started coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They issued a “buy” rating and a $125.00 price target on the stock. Royal Bank of Canada boosted their price objective on shares of Gilead Sciences from $84.00 to $90.00 and gave the company a “sector perform” rating in a research report on Wednesday, February 12th. Finally, Maxim Group downgraded Gilead Sciences from a “buy” rating to a “hold” rating in a research note on Friday, November 8th. Eleven equities research analysts have rated the stock with a hold rating, fifteen have given a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat, Gilead Sciences presently has a consensus rating of “Moderate Buy” and a consensus target price of $102.08.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.